{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:20:04Z","timestamp":1784298004878,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005677","name":"Deutsche Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["13R\/2017"],"award-info":[{"award-number":["13R\/2017"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Reverse transcriptases (RT) are essential tools in BCR::ABL1 fusion transcript monitoring in chronic myeloid leukemia (CML). The RT type and cDNA priming method may impair the stoichiometry of cDNA synthesis, thereby potentially introducing a bias in BCR::ABL1 qRT-PCR data. Using the Acrometrix\u2122 BCR::ABL1 reference panel and 37 clinical specimens, we have comparatively investigated the performance of the RTs MLV and SuperScript IV with random hexamer vs. target-specific priming. Quantitative RT-PCR results identified the priming type and RT type as major factors for diagnostic data variation, mainly due to the different efficacies of processing BCR::ABL1 low-copy-numbers (&lt;50) compared to GUSB or ABL1 high-copy targets. The impairment of SuperScript IV in processing low- and high-copy-number RNA targets equally was not reflected by the diagnostically relevant Log (BCR::ABL1\/GUSB%) values. Therefore, the correct representation of housekeeping and BCR::ABL1 target genes should have priority when aiming at as high a number of housekeeping gene copies as possible. Our data suggest that for improving BCR::ABL1 assay sensitivity, increased RNA\/cDNA amounts and the use of distinct RT\/priming combinations are advantageous. However, for inter-laboratory harmonization, the proper conversion factor according to the CML international standard (IS) has to be reevaluated each time the grade of RT is changed.<\/jats:p>","DOI":"10.3390\/cancers15153914","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T09:24:24Z","timestamp":1690881864000},"page":"3914","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reverse Transcription Can Critically Impact the Diagnostic Outcome of BCR::ABL1 Quantitative Real-Time RT-PCR"],"prefix":"10.3390","volume":"15","author":[{"given":"Birgit","family":"Spiess","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Kleiner","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Tarnopolscaia","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Naumann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fabarius","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-5785","authenticated-orcid":false,"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2490-9321","authenticated-orcid":false,"given":"Wolfgang","family":"Seifarth","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.2147\/CMAR.S232752","article-title":"Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances","volume":"12","author":"Cumbo","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1007\/s00277-015-2315-1","article-title":"Molecular monitoring of chronic myeloid leukemia: Principles and interlaboratory standardization","volume":"94","author":"Cross","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Jovanovski, A., Petiti, J., Giugliano, E., Gottardi, E.M., Saglio, G., Cilloni, D., and Fava, C. (2020). Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR. Cancers, 12.","DOI":"10.3390\/cancers12113287"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-019-0729-2","article-title":"Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: Recent advances and remaining challenges","volume":"12","author":"Soverini","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Spiess, B., Rinaldetti, S., Naumann, N., Galuschek, N., Kossak-Roth, U., Wuchter, P., Tarnopolscaia, I., Rose, D., Voskanyan, A., and Fabarius, A. (2019). Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214305"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","article-title":"Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia","volume":"153","author":"Foroni","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Spiess, B., Naumann, N., Galuschek, N., Rinaldetti, S., Kossak-Roth, U., Tarnopolscaia, I., Felde, E., Fabarius, A., Hofmann, W.K., and Sau\u00dfele, S. (2018). The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0196326"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jmoldx.2013.02.004","article-title":"Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples","volume":"15","author":"Stanoszek","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/bies.20749","article-title":"When good transcripts go bad: Artifactual RT-PCR \u2018splicing\u2019 and genome analysis","volume":"30","author":"Roy","year":"2008","journal-title":"BioEssays"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1111\/ijlh.13004","article-title":"Impact of assay procedures on detection of MR(4.5) status in chronic myeloid leukemia: Optimization of cDNA synthesis","volume":"41","author":"Jeromin","year":"2019","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_14","first-page":"267","article-title":"Viral polymerases","volume":"234","author":"Andino","year":"2017","journal-title":"Virus Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1128\/jvi.68.8.4747-4758.1994","article-title":"Strand displacement synthesis capability of Moloney murine leukemia virus reverse transcriptase","volume":"68","author":"Whiting","year":"1994","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"167507","DOI":"10.1016\/j.jmb.2022.167507","article-title":"Novel RNase H Inhibitors Blocking RNA-directed Strand Displacement DNA Synthesis by HIV-1 Reverse Transcriptase","volume":"434","author":"Kang","year":"2022","journal-title":"J. Mol. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1073\/pnas.76.9.4355","article-title":"Synthesis of a 600-nucleotide-long plus-strand DNA by virions of Moloney murine leukemia virus","volume":"76","author":"Mitra","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/293543a0","article-title":"Nucleotide sequence of Moloney murine leukaemia virus","volume":"293","author":"Shinnick","year":"1981","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1042\/bj3370231","article-title":"Differential priming of RNA templates during cDNA synthesis markedly affects both accuracy and reproducibility of quantitative competitive reverse-transcriptase PCR","volume":"337","author":"Zhang","year":"1999","journal-title":"Biochem. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.yexmp.2009.07.005","article-title":"Higher random oligo concentration improves reverse transcription yield of cDNA from bioptic tissues and quantitative RT-PCR reliability","volume":"87","author":"Nardon","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2144\/000112153","article-title":"Reverse transcription using random pentadecamer primers increases yield and quality of resulting cDNA","volume":"40","author":"Stangegaard","year":"2006","journal-title":"BioTechniques"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0003-2697(02)00021-0","article-title":"Sensitivity and accuracy of quantitative real-time polymerase chain reaction using SYBR green I depends on cDNA synthesis conditions","volume":"307","author":"Fijnvandraat","year":"2002","journal-title":"Anal. Biochem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tibtech.2020.06.008","article-title":"Reverse Transcriptase: From Transcriptomics to Genome Editing","volume":"39","year":"2021","journal-title":"Trends Biotechnol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/leu.2016.90","article-title":"Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale","volume":"30","author":"Cross","year":"2016","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"Cross","year":"2009","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1373\/clinchem.2019.307835","article-title":"Performance Comparison of Reverse Transcriptases for Single-Cell Studies","volume":"66","author":"Zucha","year":"2020","journal-title":"Clin. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fbioe.2019.00358","article-title":"Normalization Methods for the Analysis of Unbalanced Transcriptome Data: A Review","volume":"7","author":"Liu","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Saussele","year":"2016","journal-title":"Leukemia"},{"key":"ref_31","first-page":"106","article-title":"TKI discontinuation in CML: How do we make more patients eligible? How do we increase the chances of a successful treatment-free remission? Hematology. American Society of Hematology","volume":"2021","author":"Hochhaus","year":"2021","journal-title":"Educ. Program"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41375-021-01173-w","article-title":"Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI","volume":"35","author":"Richter","year":"2021","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/s41375-018-0055-7","article-title":"Defining therapy goals for major molecular remission in chronic myeloid leukemia: Results of the randomized CML Study IV","volume":"32","author":"Saussele","year":"2018","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.2020005514","article-title":"Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia","volume":"137","author":"Shanmuganathan","year":"2021","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3914\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:23:49Z","timestamp":1760127829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":34,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15153914"],"URL":"https:\/\/doi.org\/10.3390\/cancers15153914","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}